Found: 7
Select item for more details and to access through your institution.
Ribavirin dosing in chronic hepatitis C: Application of population pharmacokinetic-pharmacodynamic models<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2002, v. 72, n. 4, p. 349, doi. 10.1067/mcp.2002.127112
- By:
- Publication type:
- Article
Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C<sup>*</sup>.
- Published in:
- Clinical Pharmacology & Therapeutics, 2001, v. 69, n. 6, p. 407, doi. 10.1067/mcp.2001.115872
- By:
- Publication type:
- Article
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
- Published in:
- 2000
- By:
- Publication type:
- journal article
A maximum likelihood approach for estimating the QT correction factor using mixed effects model.
- Published in:
- Statistics in Medicine, 2003, v. 22, n. 11, p. 1901, doi. 10.1002/sim.1434
- By:
- Publication type:
- Article
p53[sup +/-] Hemizygous Knockout Mouse: Overview of Available Data.
- Published in:
- Toxicologic Pathology, 2001, v. 29, p. 30, doi. 10.1080/019262301753178465
- By:
- Publication type:
- Article
p53 +/- Hemizygous Knockout Mouse: Overview of Available Data.
- Published in:
- Toxicologic Pathology, 2001, v. 29, n. 1S, p. 30, doi. 10.1080/019262301753178465
- By:
- Publication type:
- Article
Statistical Issues in the Design and Analysis of Carcinogenicity Bioassays.
- Published in:
- Toxicologic Pathology, 1983, v. 11, n. 1, p. 83, doi. 10.1177/019262338301100114
- By:
- Publication type:
- Article